This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cramer's 'Mad Money' Recap: Biotech in the Spotlight

Click here for an archive of Cramer's "Mad Money" Recaps.

There is a tug of war for dollars on Wall Street this week. The tug of war is between technology and biotech. Technology won on Monday night. But Tuesday night belonged to biotech.

On the heel of Tuesday's news, the growth dollars are heading to biotech after Amgen (AMGN - Get Report) and Gilead (GILD - Get Report) reported great second-quarter numbers after the closing bell.

But Jim Cramer told his "Mad Money" viewers on CNBC that biotech will do especially well in the future -- especially if investors compare them with the Big Pharma stocks of today.

Investors also will be looking to put money to work in Genentech (DNA), Celgene (CELG - Get Report) and Genzyme (GENZ). In fact, Cramer said, he never wants to hear about Pfizer (PFE - Get Report) and Merck (MRK - Get Report) again.

"We want to be looking for stocks that will be in our kids' medicine cabinets," he said. Pfizer and Merck have the stuff that is in cabinets today, he said.

What's more, Cramer said that Big Pharma doesn't innovate anymore. They just repackage stuff so that they can squeeze out every last dime. The biotech companies are the future of pharmaceuticals, he said.

"Get into biotech now to make money off of lifesaving drugs," Cramer concluded.

Motorola CEO Talk

Motorola (MOT) reported a great second quarter after the bell on Tuesday night. It reported better-than-expected earnings and sales. But the stock sold off after hours. Cramer talked with CEO Ed Zander about the quarter and about the company's future. Zander outlined a host of products that will continue to keep the momentum going at Motorola.

After chatting with Zander, Cramer said that the stock ran up in anticipation of great numbers. Cramer now thinks that the stock might pull back, however. And if it does, he said that he would definitely be a buyer. Cramer also pointed out that Motorola would be meeting with analysts next week to discuss business as well. Finally, if Motorola had reported its numbers by itself on Tuesday -- without Yahoo! (YHOO) and Lucent (LU) also reporting -- the stock would have been up on Tuesday night. Instead, it was down. Cramer believes weakness in Motorola stock is a gift, he said.

The 'Lightning Round'


Cramer was bullish on: Gold Kist (GKIS), Schering-Plough (SGP), Homex (HXM), WCI Communities (WCI), Syneron Medical (ELOS - Get Report), Apache (APA - Get Report), SCP Pool (POOL - Get Report), Chicago Mercantile (CME - Get Report), Expeditors (EXPD - Get Report), Allscripts Healthcare (MDRX - Get Report), Titanium Metals (TIE), Orleans Homebuilders (OHB), BRE Properties (BRE), International Paper (IP - Get Report), Microtune (TUNE), Logitech (LOGI - Get Report), Novatel (NGPS).
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MCGC $0.00 0.00%
TIE $16.50 0.00%
APA $54.20 -0.37%
AMGN $158.94 0.40%
AMD $3.71 4.50%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs